References:
1 Fritchie KJ, Torres-Mora J, Inwards C, et al. Xanthogranulomatous
epithelial tumor: report of 6 cases of a novel, potentially deceptive
lesion with a predilection for young women. Mod Pathol.
2020;33(10):1889-1895. doi:10.1038/s41379-020-0562-8
2 Dehner CA, Baker JC, Bell R, et al. Xanthogranulomatous epithelial
tumors and keratin-positive giant cell-rich soft tissue tumors: two
aspects of a single entity with frequent HMGA2-NCOR2 fusions. Mod
Pathol. 2022;35(11):1656-1666. doi:10.1038/s41379-022-01115-6
3 Agaimy A, Michal M, Stoehr R, et al. Recurrent novel HMGA2-NCOR2
fusions characterize a subset of keratin-positive giant cell-rich soft
tissue tumors. Mod Pathol. 2021;34(8):1507-1520.
doi:10.1038/s41379-021-00789-8
4 Svantesson T, van Oudenaarde K, Fuchs B, Bode B, Vogetseder A.
Xanthogranulomatous epithelial tumor: a novel entity of uncertain
biologic potential. Arch Clin Cases. 2023;10(3):142-145. Published 2023
Oct 5. doi:10.22551/2023.40.1003.10261
5 van der Heijden L, Dijkstra PDS, Blay JY, Gelderblom H. Giant cell
tumour of bone in the denosumab era. Eur J Cancer. 2017;77:75-83.
doi:10.1016/j.ejca.2017.02.021